May-Hau Didier Ismael, Bárcenas-López Diego Alberto, Núñez-Enríquez Juan Carlos, Bekker-Méndez Vilma Carolina, Beltrán-Anaya Fredy Omar, Jiménez-Hernández Elva, Ortíz-Maganda Mónica Patricia, Guerra-Castillo Francisco Xavier, Medina-Sanson Aurora, Flores-Lujano Janet, Martín-Trejo Jorge Alfonso, Peñaloza-González José Gabriel, Velázquez-Aviña Martha Margarita, Torres-Nava José Refugio, Hernández-Echáurregui Gabriela Alicia, Espinosa-Elizondo Rosa Martha, Gutiérrez-Rivera María de Lourdes, Sanchez-Hernandez Rodrigo, Pérez-Saldívar María Luisa, Flores-Villegas Luz Victoria, Merino-Pasaye Laura Elizabeth, Duarte-Rodríguez David Aldebarán, Mata-Rocha Minerva, Sepúlveda-Robles Omar Alejandro, Rosas-Vargas Haydeé, Hidalgo-Miranda Alfredo, Mejía-Aranguré Juan Manuel, Jiménez-Morales Silvia
Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Programa de Maestría en Investigación Clínica Experimental en Salud, Universidad Nacional Autónoma de Mexico, México City, Mexico.
Front Oncol. 2022 Jun 2;12:887766. doi: 10.3389/fonc.2022.887766. eCollection 2022.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most frequent pediatric cancer worldwide. Despite improvements in treatment regimens, approximately 20% of the cases cannot be cured, highlighting the necessity for identifying new biomarkers to improve the current clinical and molecular risk stratification schemes. We aimed to investigate whether is a biomarker in ALL and to explore its expression level in other human cancer types.
A nested case-control study including Mexican children with BCP-ALL was conducted. expression was evaluated by qRT-PCR using hydrolysis probes. To validate our findings, RNA-seq expression data from BCP-ALL and normal tissues were retrieved from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Genotype-Tissue Expression (GTEx) repositories, respectively. expression was also evaluated in solid tumors by downloading available data from The Cancer Genome Atlas (TCGA).
A lower expression of in BCP-ALL cases compared to normal subjects was observed ( < 0.05). ALL patients who carry the fusion gene displayed lower expression of in contrast to other BCP-ALL molecular subtypes ( < 0.04). underexpression was associated with a high risk to relapse (HR = 1.946, 95% CI = 1.213-3.120) and die (HR = 2.073, 95% CI = 1.211-3.547). Patients with and underexpression of had the worst prognosis (DFS: HR = 12.24, 95% CI = 5.04-29.71; OS: HR = 11.19, 95% CI = 26-32). TCGA data analysis revealed that underexpression of is also associated with poor clinical outcomes in six new reported tumor types.
Our findings suggest that is a biomarker of poor prognosis in BCP-ALL and other types of cancer. We observed an association between the expression of and and the risk to relapse and die in BCP-ALL, which is worse in positive cases displaying underexpression of Experimental studies are needed to provide insight into the and relationship.
B细胞前体急性淋巴细胞白血病(BCP-ALL)是全球最常见的儿童癌症。尽管治疗方案有所改进,但仍有大约20%的病例无法治愈,这凸显了识别新生物标志物以改进当前临床和分子风险分层方案的必要性。我们旨在研究[具体基因名称未给出]是否为ALL中的一种生物标志物,并探索其在其他人类癌症类型中的表达水平。
开展了一项嵌套病例对照研究,纳入患有BCP-ALL的墨西哥儿童。使用水解探针通过qRT-PCR评估[具体基因名称未给出]的表达。为验证我们的发现,分别从治疗应用研究以生成有效治疗方法(TARGET)和基因型-组织表达(GTEx)数据库中检索BCP-ALL和正常组织的RNA-seq表达数据。还通过从癌症基因组图谱(TCGA)下载可用数据来评估实体瘤中[具体基因名称未给出]的表达。
观察到与正常受试者相比,BCP-ALL病例中[具体基因名称未给出]的表达较低(P<0.05)。与其他BCP-ALL分子亚型相比,携带[具体融合基因名称未给出]融合基因的ALL患者显示出较低的[具体基因名称未给出]表达(P<0.04)。[具体基因名称未给出]表达不足与复发风险高(HR = 1.946,95%CI = 1.213 - 3.120)和死亡风险高(HR = 2.073,95%CI = 1.211 - 3.547)相关。[具体基因名称未给出]表达缺失且[具体基因名称未给出]表达不足的患者预后最差(无病生存期:HR = 12.24,95%CI = 5.04 - 29.71;总生存期:HR = 11.19,95%CI = 26 - 32)。TCGA数据分析显示,[具体基因名称未给出]表达不足在六种新报道的肿瘤类型中也与不良临床结局相关。
我们的研究结果表明,[具体基因名称未给出]是BCP-ALL和其他癌症类型中预后不良的生物标志物。我们观察到BCP-ALL中[具体基因名称未给出]和[具体基因名称未给出]的表达与复发和死亡风险之间存在关联,在显示[具体基因名称未给出]表达不足的阳性病例中情况更糟。需要进行实验研究以深入了解[具体基因名称未给出]和[具体基因名称未给出]之间的关系。